[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100578480":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":34,"centralContacts":35,"locations":41,"responsibleParty":88,"collaborators":34,"id":92,"slug":34,"hasResults":93,"nctId":94,"briefTitle":95,"officialTitle":96,"acronym":34,"eligibilityCriteria":97,"healthyVolunteers":93,"sex":98,"minAge":99,"maxAge":100,"enrollmentInfo":101,"targetDuration":34,"studyType":104,"phases":105,"briefSummary":107,"conditions":108,"keywords":34,"overallStatus":43,"whyStopped":34,"lastUpdateSubmitDate":114,"lastUpdatePostDateStruct":115,"startDateStruct":118,"completionDateStruct":120,"leadSponsor":122,"locationsCount":123},{"fullName":5,"class":6},"The First Affiliated Hospital of Xiamen University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Two-cycle","EXPERIMENTAL","Two cycles induction chemotherapy + immunotherapy",[13],"Drug: Two-cycle induction chemotherapy + immunotherapy",{"label":15,"type":16,"description":17,"interventionNames":18},"Three-cycle","ACTIVE_COMPARATOR","Three cycles induction chemotherapy + immunotherapy",[19],"Drug: Three-cycle induction chemotherapy + immunotherapy",[21,28],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Two-cycle induction chemotherapy + immunotherapy","Two cycles of nab-paclitaxel at 260 mg\u002Fm2 on day 1, cisplatin at 25 mg\u002Fm2 from days 1 to 3, and oral S1 twice daily from days 1 to 14 (40 mg twice daily on patients with a body surface area \\[BSA\\] less than 1.25 m2, 50 mg twice daily for patients with a BSA between 1.25 and 1.5 m2, and 60 mg twice daily for patients with a BSA \\>1.5 m2). Camrelizumab was administered intravenously at a dose of 200 mg on the first day of each cycle.",[9],[27],"2",{"type":22,"name":29,"description":30,"armGroupLabels":31,"otherNames":32},"Three-cycle induction chemotherapy + immunotherapy","Three cycles of nab-paclitaxel at 260 mg\u002Fm2 on day 1, cisplatin at 25 mg\u002Fm2 from days 1 to 3, and oral S1 twice daily from days 1 to 14 (40 mg twice daily on patients with a body surface area \\[BSA\\] less than 1.25 m2, 50 mg twice daily for patients with a BSA between 1.25 and 1.5 m2, and 60 mg twice daily for patients with a BSA \\>1.5 m2). Camrelizumab was administered intravenously at a dose of 200 mg on the first day of each cycle.",[15],[33],"3",null,[36],{"name":37,"role":38,"phone":39,"phoneExt":34,"email":40},"San-Gang Wu, MD","CONTACT","865922139531","wusg@xmu.edu.cn",[42,59,73],{"facility":5,"status":43,"city":44,"state":45,"zip":46,"country":47,"cosmosGeoPoint":48,"geoPoint":53,"contacts":54},"RECRUITING","Xiamen","Fujian","361003","China",{"type":49,"coordinates":50},"Point",[51,52],118.08187,24.47979,{"lat":52,"lon":51},[55],{"name":56,"role":38,"phone":57,"phoneExt":34,"email":58},"Dan-Ping Wang","865922137569","xdfyec@sina.com",{"facility":60,"status":43,"city":61,"state":45,"zip":62,"country":47,"cosmosGeoPoint":63,"geoPoint":67,"contacts":68},"Zhangzhou Affiliated Hospital of Fujian Medical University","Zhangzhou","363099",{"type":49,"coordinates":64},[65,66],117.65556,24.51333,{"lat":66,"lon":65},[69],{"name":70,"role":38,"phone":71,"phoneExt":34,"email":72},"Gui-Ping Chen, MD","8613599592455","754514055@qq.com",{"facility":74,"status":43,"city":75,"state":76,"zip":77,"country":47,"cosmosGeoPoint":78,"geoPoint":82,"contacts":83},"Hainan General Hospital","Haikou","Hainan","570311",{"type":49,"coordinates":79},[80,81],110.34651,20.03421,{"lat":81,"lon":80},[84],{"name":85,"role":38,"phone":86,"phoneExt":34,"email":87},"Shi-Ping Yang, MD","8618976460313","shipingyang1982@163.com",{"type":89,"investigatorFullName":90,"investigatorTitle":91,"investigatorAffiliation":5,"oldNameTitle":34,"oldOrganization":34},"PRINCIPAL_INVESTIGATOR","San-Gang Wu","Clinical professor","100578480",false,"NCT06811844","Two-cycle and Three-cycle Induction Therapy With Modified TPF Regimen Combined and Camrelizumab for LANPC","Comparison of Two-cycle and Three-cycle Induction Therapy With Modified TPF Regimen Combined and Camrelizumab for Locally Advanced Nasopharyngeal Carcinoma: A Prospective, Phase II, Multicenter, Randomized Controlled Study","Inclusion Criteria:\n\n* Age: 18-65 years old;\n* Pathologically (including histology or cytology) confirmed nasopharyngeal carcinoma patients, with clinical staging T1-4N2-3M0 (according to the UICC\u002FAJCC TNM staging system, 8th edition);\n* No prior systemic treatment (surgery, radiotherapy, chemotherapy, etc.);\n* At least one measurable lesion on imaging (as per RECIST criteria version 1.1);\n* ECOG Performance Status (PS): 0-1;\n* Expected survival ≥3 months;\n* Male subjects and women of childbearing potential must use contraception from the first dose of study medication until 24 weeks after the last dose of study medication;\n* Normal major organ function, with basic normal results in hematology, biochemistry, and coagulation tests;\n* The investigator believes that the treatment will provide a survival benefit.\n\nExclusion Criteria:\n\n* Active, known, or suspected autoimmune disease;\n* Patients with hypertension that cannot be controlled to normal range despite antihypertensive medication (systolic BP \\>160 mmHg, diastolic BP \\>90 mmHg);\n* History of hereditary bleeding tendency or coagulation dysfunction. Any clinically significant bleeding symptoms within 12 weeks prior to screening, or cumulative bleeding over 50 ml in 24 hours;\n* Unwell-controlled cardiac clinical symptoms or diseases;\n* Interstitial lung disease, drug-induced pneumonia, steroid-treated radiation pneumonitis, active pneumonia with symptoms, or severe pulmonary dysfunction;\n* Active hepatitis B (HBV DNA ≥2000 IU\u002FmL or 10\\^4 copies\u002FmL), hepatitis C (HCV antibody positive and HCV-RNA above the lower limit of detection of the assay);\n* Allergy to any of the study drugs;\n* Pregnant or breastfeeding women;\n* Any other factors that, in the investigator's judgment, may cause premature termination of the study.","ALL","18 Years","65 Years",{"count":102,"type":103},208,"ESTIMATED","INTERVENTIONAL",[106],"PHASE2","This prospective, phase II, multicenter, randomized controlled study aims to compare the complete response rate and long-term survival outcomes of two-cycle and three-cycle induction therapy with modified TPF regimens combined with camrelizumab in patients with locally advanced nasopharyngeal carcinoma.",[109,110,111,112,113],"Nasopharyngeal Neoplasms","PD-1 Inhibitor","Induction Therapy","Complete Response","Chemotherapy","2025-06-30",{"date":116,"type":117},"2025-07-01","ACTUAL",{"date":119,"type":117},"2025-02-25",{"date":121,"type":103},"2029-12-31",{"name":5,"class":6},3]